Trial · NCT07884877
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 12-Month Progression-Free Survival Rate | 12 months from start of radiotherapy | Proportion of participants alive without progression (RECIST v1.1) or death at 12 months from the start of radiotherapy, estimated by the Kaplan-Meier method. |
| Secondary | Progression-Free Survival | Up to 36 months | Time from start of radiotherapy to progression (RECIST v1.1) or death from any cause, whichever occurs first; median estimated by the Kaplan-Meier method. |
| Secondary | 6-Month Progression-Free Survival Rate | 6 months from start of radiotherapy | Proportion of participants alive without progression (RECIST v1.1) or death at 6 months from the start of radiotherapy, estimated by the Kaplan-Meier method. |
| Secondary | Objective Response Rate | Up to 36 months | Proportion of participants with a best overall response of complete or partial response per RECIST v1.1. |
| Secondary | Overall Survival | Up to 36 months | Time from start of radiotherapy to death from any cause. |
| Secondary | Disease Control Rate | Up to 36 months | Proportion of participants with a best overall response of complete response, partial response, or stable disease per RECIST v1.1. |
| Secondary | Local Recurrence-Free Survival | Up to 36 months | Time from start of radiotherapy to first recurrence or progression within the irradiated lesion (PTV). |
| Secondary | Incidence of Adverse Events | Up to 36 months | Type, frequency, and severity of adverse events graded by NCI CTCAE v5.0. |
| Other | Change in Peripheral Immune Cell Subsets and Plasma Cytokines | Before each pulse and 3 months after radiotherapy | Immune phenotyping of PBMCs by flow cytometry and plasma cytokine levels (e.g., IL-6, IL-8, IL-10, IFN-gamma). |
| Other | Change in CT Radiomic Features | Before each pulse | Radiomic features extracted from planning CT before each pulse. |
| Other | Patient-Reported Adverse Events (PRO-CTCAE) | Baseline through 36 months | Symptomatic adverse events reported by participants using the PRO-CTCAE core set. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07884877/registered